Received Nov 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 2 | BG5J4 | IM / LA |
The patient received an inappropriate dose of the vaccine. They had previously received this vaccine in January of 2024 and there is currently no recommendation to receive any further doses. Patient claims to have not experienced any ill effects of receiving the extra dose.
none
dyslipidemia, high blood pressure, and gerd
amlodipine-olmesartan, rosuvastatin, pantoprazole, xarelto, and testosterone
n/a